

EADV 2025

DO NOT MISS HIGHLIGHTS IN PSORIATIC DISEASE

SEPTEMBER 2025



NEWSLETTER

TABLE OF CONTENTS

Basic Science Highlights • P. 2-4

Clinical Highlights • P. 5-8

Treatment Highlights • P. 9-10

EADV 2025 GRAPPA Virtual Congress Highlights • P. 12

Y-GRAPPA members prepared this Newsletter. It highlights some of the very interesting abstracts on psoriatic disease that will be presented at the 2025 EADV congress.



Ahmet Uğur Atılan

COORDINATOR

**&
BASIC SCIENCE HIGHLIGHTS**



Hanna Johnsson

COORDINATOR



Daniela Tovar

FORMATTING / LAYOUT



Dimitri Luz
BASIC SCIENCE HIGHLIGHTS



Daniel Barquero
CLINICAL HIGHLIGHTS



Yusuf Can Edek
CLINICAL & TREATMENT HIGHLIGHTS

BASIC SCIENCE HIGHLIGHTS



- [Dr. Ahmet Uğur Atılan, MD, MSc](#)
- Y-GRAPPA Newsletter Sub-Committee
- GRAPPA Psoriasis Treatment Slide Library (2025 update)



[Ahmet Uğur Atılan](#)



[@ai.dermatologist](#)

Assistant Professor of Dermatology & Venereology,
Pamukkale University Faculty of Medicine, Denizli, Türkiye

THE EFFECT OF PLASMA EXOSOMAL MICRORNA-148A-3P ON THE CD4+ T CELL FUNCTION AND ITS MECHANISM IN THE PATHOGENESIS OF PSORIASIS

MD, PhD Luo Quan (Guangzhou, China)

POSTER ID P2089

E-Poster



Why important?

This study explores the upstream regulatory impact of microRNA-148a-3p on CD4+ T cells, a crucial yet underexamined immune axis in psoriasis. Exosomal microRNAs could represent a non-invasive biomarker and a future target for personalized psoriasis therapies.

SPATIAL TRANSCRIPTOMIC PROFILING REVEALS BODY SITE-SPECIFIC INFLAMMATORY DIFFERENCES IN PSORIASIS LESIONS

MD, PhD Thomas Emmanuel (Aarhus, Denmark)

POSTER ID P2224

E-Poster, Session: Psoriasis



Why important?

Spatial transcriptomics reveals how inflammation differs between scalp, trunk, or extremities—challenging the one-size-fits-all view of lesion biology. May lead to site-specific treatments or refined severity scoring systems in clinical trials.

BASIC SCIENCE HIGHLIGHTS

CRYPTOCHROME 2 ATTENUATES PSORIATIC SKIN INFLAMMATION BY SUPPRESSING KERATINOCYTE PROLIFERATION AND INFLAMMATORY RESPONSES

Dr. Jing Zhou (Shanghai, China)

POSTER ID P2099

E-Poster, Session: Psoriasis



Why important?

This study connects circadian rhythm proteins (cryptochromes) to inflammation and keratinocyte hyperproliferation, offering a novel chrono-therapeutic perspective. CRY2 might be a new molecular checkpoint linking skin biology and immune regulation.

TARGETING NEUROGENIC SKIN INFLAMMATION MITIGATES STRESS-EXACERBATED PSORIASIS: INSIGHTS FROM A STRESS-RESPONSIVE "HUMANIZED" PSORIASIS MOUSE MODEL

Dr. Amos Gilhar (Haifa, Israel)

POSTER ID P2571

E-Poster, Session: Psoriasis



Why important?

·Demonstrates how neuroimmune mechanisms exacerbate psoriasis via stress-related signalling, reinforcing the need for psychosomatic perspectives in dermatology. A humanized mouse model strengthens translational validity and opens doors for neurokinin-targeted interventions.

BASIC SCIENCE HIGHLIGHTS



- Dimitri Luz MD, MsC, MBA
- Dermco, Perth, Australia
- Y-grappa: rheum-derm collab leader
- Full GRAPPA member



[Dimitri Luz](#)

INHIBITION OF HUR/ELAVL1 ACTIVITY IN HUMAN PSORIATIC KERATINOCYTES AND LYMPHOCYTES AS A NEW THERAPEUTIC STRATEGY

Dr. Gianluca Nazzaro (Milan, Italy)

POSTER ID P2143

E-Poster



ADIPOSE-DERIVED REGENERATIVE THERAPY FOR PSORIASIS VULGARIS: UNLOCKING NEW FRONTIERS IN AUTOIMMUNE SKIN DISEASE TREATMENT

Laurentia Fidella Averina Setia Santoso (Bandung, Indonesia)

POSTER ID P2087

E-Poster



DISTINCT GUT MICROBIOTA SIGNATURES ASSOCIATED WITH PROGRESSION OF ATHEROSCLEROSIS IN PSORIASIS PATIENTS: RESULTS FROM THE EDSAP STUDY

Dr. PhD Carlota Abbad-Jaime de Aragón (Madrid, Spain)

POSTER ID P2087

E-Poster, Session: Psoriasis



CLINICAL HIGHLIGHTS



- Yusuf Can Edek, MD
- Research Assistant of Dermatology & Venereology, Gazi University Faculty of Medicine, Ankara, Türkiye
- Member of Y-GRAPPA



s://www.linkedin.com/in/yusuf-can-edek-303a95186/

POSITIVE ASSOCIATIONS BETWEEN TRIGLYCERIDE-GLUCOSE (TYG) AND TYG-BODY MASS INDEX (TYG-BMI) WITH CARDIOVASCULAR DISEASE IN PATIENTS WITH PSORIASIS: CROSS-SECTIONAL RESULTS FROM THE SPEECH

Dr. Ying Li (Shanghai, China)

POSTER ID P2045

E-Poster, Wednesday, 17 Sep, 07:00 – 07:00 CEST Session: Psoriasis



Why important?

Cardiovascular disease is a significant comorbidity in patients with psoriasis, and scoring systems for assessing this comorbidity will be helpful to be able to address it. It is noteworthy that this study used risk analysis using easily assessed factors such as BMI, glucose, and triglyceride.

SMOKING CESSATION, WEIGHT CHANGE, AND PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

Prof. Seong Jin Jo (Seoul, Korea, Rep. of South)

POSTER ID P2095

E-Poster, Wednesday, 17 Sep, 07:00 – 07:00 CEST Session: Psoriasis



Why important?

Smoking and obesity are factors that contribute to treatment resistance in psoriasis. This nationwide study evaluating the effects of smoking cessation and weight changes on psoriasis will guide the evaluation of the effects of these two variables on the disease.

CLINICAL HIGHLIGHTS

IMPACT OF A JOINT DERMATOLOGY-RHEUMATOLOGY CLINIC ON THE MANAGEMENT OF PSORIASIS AND PSORIATIC ARTHRITIS: A REAL-WORLD EXPERIENCE FROM A SPANISH HOSPITAL

Dr. Samuel Corral Pavanelo (Málaga, Spain)

POSTER ID P2166

E-Poster, Wednesday, 17 Sep, 07:00 – 07:00 CEST Session: Psoriasis



Why important?

This study is very important as it demonstrates the importance of dermatologists and rheumatologists working together in the management of psoriasis, which requires a multimodal treatment approach.

THE SLEEPLESS CYCLE: UNRAVELING THE INTERPLAY BETWEEN SLEEP DISTURBANCES AND QUALITY OF LIFE IN PSORIASIS

MD, PhD Sueli Coelho Da Silva Carneiro (Rio De Janeiro, Brazil)

POSTER ID P2682

E-Poster, Wednesday, 17 Sep, 07:00 – 07:00 CEST Session: Psoriasis



Why important?

Studies investigating the effects of chronic inflammatory skin diseases on sleep are increasingly appearing in the literature. This study evaluates comorbid sleep disorders in patients with psoriasis.

CLINICAL HIGHLIGHTS



- Dr. Daniel Barquero Orias, MD
- Dermatologist, Caja Costarricense del Seguro Social, Costa Rica
- Contributor, GRAPPA Psoriasis Slide Library Spanish



[Daniel Barquero Orias](#)

RECOMMENDATIONS FOR APPROACH TO GENITAL PSORIASIS PHYSICAL EXAM, DIAGNOSIS, AND TREATMENT: A PROGRESS REPORT FROM THE GENITAL PSORIASIS WELLNESS CONSORTIUM CONSENSUS PANEL

Dr. Michael Payette (Cromwell, United States)

POSTER ID P2042

E-Poster Wednesday, 17 Sep, 07:00 – 07:00 CEST

Session: Psoriasis



Why important?

This consensus report is important because it provides unified, evidence-based recommendations for the physical exam, diagnosis, and treatment of genital psoriasis—an often underrecognized yet highly impactful manifestation of the disease—helping clinicians improve patient care and quality of life.

ENHANCING CLINICAL EVALUATION OF PSORIASIS SEVERITY WITH AI-BASED PASI FEATURE SCORING

PhD Paul Fricker (Ramonville–St–Agne, France)

POSTER ID P3131

E-Poster, Session: Psoriasis



Why important?

This work is important because it introduces AI-driven PASI feature scoring to standardize and enhance the accuracy of psoriasis severity assessment, reducing inter-observer variability and supporting more consistent clinical and research outcomes

CLINICAL HIGHLIGHTS

MUCOSAL PSORIASIS: A DESCRIPTIVE CLINICAL AND DERMOSCOPIC STUDY

Dr. Ghita Gmira (Fez, Morocco)

POSTER ID P3404

E-Poster, Session: Psoriasis



Why important?

This study is important because it highlights the clinical and dermoscopic characteristics of mucosal psoriasis, a rare and underdiagnosed manifestation, thereby improving recognition and guiding more accurate diagnosis and management.

SUBCLINICAL CARDIAC ORGAN DAMAGE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

Dr. Kåre Steinar Tveit (Bergen, Norway)

POSTER ID P3776

E-Poster, Session: Psoriasis



Why important?

This study is important because it uncovers the presence of subclinical cardiac organ damage in patients with moderate to severe psoriasis, emphasizing the need for early cardiovascular risk assessment and integrated management in this population

INVESTIGATION OF PSORIATIC NAIL FINDINGS BY CLINICAL, DERMOSCOPIC AND CAPILLAROSCOPIC METHODS AND THEIR ASSOCIATION WITH PSORIATIC ARTHRITIS

Dr. med. Halime Nur Holoğlu Bulut (Ankara, Türkiye)

POSTER ID P3540

E-Poster, Session: Psoriasis



Why important?

This study is important because it examines psoriatic nail changes using multiple diagnostic methods and links them to psoriatic arthritis, offering potential for earlier detection and better risk stratification of joint involvement in psoriasis patients.

TREATMENT HIGHLIGHTS



- Yusuf Can Edek, MD
- Research Assistant of Dermatology & Venereology,
- Gazi University Faculty of Medicine, Ankara, Türkiye
- Member of Y-GRAPPA



[s://www.linkedin.com/in/yusuf-can-edek-303a95186/](https://www.linkedin.com/in/yusuf-can-edek-303a95186/)

CLINICAL EFFECTIVENESS OF BIMEKIZUMAB IN RECALCITRANT AND DIFFICULT-TO-TREAT PSORIASIS AREAS (SCALP, GENITAL, NAILS AND PALMOPLANTAR SITES): A PROSPECTIVE OBSERVATIONAL STUDY IN REAL-LIFE CLINICAL PRACTICE.

Dr. Marina Torrent García (Cartagena, Spain)

POSTER ID P2141

E-Poster, Wednesday, 17 Sep, 07:00 – 07:00 CEST Session: Psoriasis



Why important?

Data regarding the use of bimekizumab in patients with psoriasis are increasing in the literature. It is striking that this study evaluated the effectiveness of bimekizumab in recalcitrant and difficult-to-treat psoriasis areas.

PREDICTIVE FACTORS AND BIOMARKERS FOR EARLY PASI100 RESPONSE TO BIOLOGIC THERAPIES IN PSORIASIS PATIENTS: A 10-YEAR SINGLE-CENTER REAL-WORLD STUDY

MD Gullu Gencebay (Istanbul, Türkiye)

POSTER ID P2076

E-Poster, Wednesday, 17 Sep, 07:00 – 07:00 CEST Session: Psoriasis



Why important?

PASI90 and PASI100 responses are more frequently achieved with the use of biologic agents in the treatment of psoriasis. Therefore, rapid response to these treatments has emerged as an important factor in increasing treatment success. This study is important for evaluating the factors associated with early PASI100 responses.

TREATMENT HIGHLIGHTS

PERSONALISING PSORIASIS TREATMENT USING ARTIFICIAL INTELLIGENCE PREDICTIVE MODELS – A PILOT STUDY.

Dr. Emily Pender (Dublin, Ireland)

POSTER ID P3482

E-Poster, Session: Psoriasis



Why important?

The use of artificial intelligence in disease diagnosis and monitoring is increasing. This study's evaluation of personalized treatment selection in psoriasis patients through artificial intelligence is noteworthy.

SKIN-CARDIOVASCULAR CO-BENEFITS IN PSORIASIS BIOLOGIC THERAPY: SYNCHRONIZED IMPROVEMENT OF CUTANEOUS LESIONS AND CORONARY INFLAMMATION

Dr. Jingwen Wu (Shanghai, China)

POSTER ID P2479

E-Poster, Session: Psoriasis




Why important?

One of the key advantages of biologic agents is their effectiveness in treating psoriasis as well as in treating psoriasis-related comorbidities. It is noteworthy that this study examined the effects of biologic agents on both cutaneous lesions and coronary inflammation.

Curious About What's Next?

Follow GRAPPA on social media and never miss a moment — from congress highlights to exclusive content and ongoing research insights.



Follow us on [LinkedIn](#) 

Follow us on [@GrappaO](#) 

Follow us on [@grappanetwork](#) 



Y-GRAPPA

YOUNG GROUP FOR RESEARCH
AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS

GRAPPA

Virtual Congress Highlights

EADV 2025

OF PSORIATIC DISEASE

REGISTER NOW!

FEATURING:



Johann Gudjonsson
USA



Álvaro González Cantero
Spain



Ana Lopez Ferrer
Spain



Ahmet Uğur Atılan
Turkey



Maria-Angeliki Gkini
UK



Yusuf Can Edek
Turkey

MODERATORS:



Lourdes Perez Chada
USA



Fabian Proft
Germany



Maarten de Wit
Netherlands

PRP:

ONLINE EVENT



WEDNESDAY
OCTOBER 1



10:00-11:30 AM EDT
4:00-5:30 PM CEST



SCAN ME



Thank you for being part of the Young GRAPPA community.

Y-GRAPPIAns

YOUNG GROUP FOR RESEARCH
AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS